亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Long-term efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a prospective real-world cohort study in China

作者
Yuyi Wang,Ruiling Jia,Qin Hu,Xiao Tao,Qi He,Guangying Luo,Qiong Xiong,Zhongyu Zhang,Yujuan Xiao,Yi Liu
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:15: 1419164-1419164 被引量:9
标识
DOI:10.3389/fimmu.2024.1419164
摘要

Backgrounds: Dupilumab has demonstrated remarkable efficacy and safety in clinical trials for moderate-to-severe atopic dermatitis (AD). However, long-term real-world evidence, especially in the Chinese population, remains limited. Objective: To investigate the long-term efficacy and safety of dupilumab for moderate-to-severe AD in a real-world clinical setting in China and analyze factors that may influence its long-term treatment outcomes. Methods: This prospective, observational real-world study included moderate-to-severe AD patients from the AD cohort of the dermatology department of Chongqing Hospital of Traditional Chinese Medicine who received dupilumab treatment for≥52 weeks. Efficacy and adverse events were assessed at baseline, weeks 4, 16, 24, and 52. Multivariate logistic regression analysis was used to identify predictive factors for achieving EASI 50 and EASI 75 at week 52. Results: A total of 124 patients were included. At week 52, EASI, SCORAD, IGA, NRS, and DLQI scores were significantly improved compared to baseline. The proportions of patients achieving EASI-50/75 were 50.81%/29.84%, 72.58%/42.74%, 75%/53.23%, and 67.74%/41.94% at weeks 4, 16, 24 and 52, respectively. Female sex, absence of atopic comorbidities, higher baseline EASI, and medication compliance were positive predictive factors for 52-week EASI-50/75. Eosinophil elevation predicted lower EASI-50 attainment. Nineteen adverse events occurred during the 52-week period (incidence rate: 14.52%), mostly mild and manageable. Conclusions: Dupilumab demonstrated significant efficacy and a low incidence of adverse events over 52 weeks in Chinese patients with moderate-to-severe AD, making it an effective and safe long-term treatment option. Predictive factors were identified to guide treatment optimization.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
踏实莛发布了新的文献求助10
6秒前
17秒前
20秒前
NinaKhan657发布了新的文献求助30
22秒前
24秒前
28秒前
现代火车发布了新的文献求助10
30秒前
WEileen完成签到 ,获得积分0
43秒前
47秒前
Herrily完成签到,获得积分10
1分钟前
1分钟前
1分钟前
mayberichard完成签到,获得积分10
2分钟前
美好傲蕾完成签到,获得积分10
2分钟前
忘乎所以完成签到,获得积分10
2分钟前
cloudy完成签到,获得积分10
2分钟前
丰富广缘完成签到,获得积分10
2分钟前
愤怒的衬衫完成签到,获得积分10
2分钟前
求求了给篇文献完成签到,获得积分10
2分钟前
mycn完成签到,获得积分10
2分钟前
开朗雅霜完成签到,获得积分10
2分钟前
温暖友易完成签到,获得积分10
2分钟前
yan完成签到,获得积分10
2分钟前
顺利毛豆完成签到,获得积分10
2分钟前
沐雨汐完成签到,获得积分10
2分钟前
baa完成签到,获得积分10
2分钟前
舒适的妍完成签到,获得积分10
2分钟前
zheng完成签到,获得积分10
2分钟前
花开富贵完成签到,获得积分10
2分钟前
陈微完成签到,获得积分10
2分钟前
完美梦之完成签到,获得积分10
2分钟前
美满尔蓝完成签到,获得积分10
2分钟前
慢波完成签到,获得积分10
2分钟前
教育邮箱完成签到,获得积分10
2分钟前
腼腆的冰安完成签到,获得积分10
2分钟前
剑剑完成签到,获得积分10
2分钟前
dingyushu完成签到,获得积分10
2分钟前
聪明的羿完成签到,获得积分10
2分钟前
du完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195167
求助须知:如何正确求助?哪些是违规求助? 9580893
关于积分的说明 21872961
捐赠科研通 7795146
什么是DOI,文献DOI怎么找? 3437967
关于科研通互助平台的介绍 2561259
邀请新用户注册赠送积分活动 2484678